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1. Introduction 
1.1. Types and sources of DNA damage 
During our lifetime, the genome is constantly being exposed to different types of damage 
caused either by exogenous sources (radiations and/or genotoxic compound) but also as 
byproducts of endogenous processes (reactive oxigen species during respiration, stalled 
forks during replication, eroded telomeres, etc).  
From a structural point of view, there are many types of DNA damage including single or 
double strand breaks, base modifications and losses or base-pair mismatches. The amount of 
lesions that we face is enormous with estimates suggesting that each of our 1013 cells has to 
deal with around 10.000 lesions per day [1]. While the majority of these events are properly 
resolved by specialized mechanisms, a deficient response to DNA damage, and particularly 
to DSB, harbors a serious threat to human health [2].  
DSB can be formed [1] following an exposure to ionizing radiation (X- or γ-rays) or clastogenic 
drugs; [2] endogenously, during DNA replication, or [3], as a consequence of reactive oxygen 
species (ROS) generated during oxidative metabolism. In addition, programmed DSB are used 
as repair intermediates during V(D)J and Class-Switch recombination (CSR) in lymphocytes 
[3], or during meiotic recombination [4]. Because of this, immunodeficiency and/or sterility 
problems are frequently associated with DDR-related pathologies.  
2. DNA repair of DSB. NHEJ and HR 
Mammalian cells are equipped with two mechanisms that repair DSB and prevent 
dangerous chromosomal rearrangements; [1] Non-homologous end joining (NHEJ), which links 
together the two ends of broken DNA by direct ligation, and [2] Homologous Recombination 
(HR), which is only available S and G2 phases when a sister chromatid can be used as a 
template for the repair reaction (see Figure 1).  
 




Figure 1. DSBs repair mechanisms. A) NHEJ. DSBs are sensed by the ring-shape heterodimer Ku70/Ku80 
which then stabilizes the two DNA ends and recruits DNA-PK. Next, DNA-PK phosphorylates and 
activates the NHEJ effector complex (ligase IV/XRC44/XLF) that finally religates the broken DNA. B) HR. 
The ATM kinase is recruited to DSB via an interaction with the MRN (Mre11-Rad50-Nbs1) complex. Once 
at the break, ATM that becomes activated, phosphorylating multiple substrates. In a reaction that depends 
in multiple endo and exonuclease activities (including Mre11, Exo1 and CtIP) DSBs are resected forming 
ssDNA strands. These ssDNA regions attract Rad51 and other associated proteins. The Rad51-coated 
nucleoprotein filaments then invade the undamaged sister strands forming HJ structures. HR is completed 
by new DNA synthesis and still to be identified HJ “resolvase” enzymes. 
2.1. Non Homologous End Joining (NHEJ) 
NHEJ is simpler and faster than HR, and can take place in any cell cycle stage. However, NHEJ 
can process altered or improper ends is thus more error-prone that HR. Therefore, HR is the 
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preferred repair mechanisms during S/G2 phases. However, due to the preponderance of the 
G0/G1 stage, NHEJ is key to safeguard genomic integrity in mammalian organisms. Moreover, 
and probably due to the larger genomes and abundant repetitive sequences which limit HR 
proficiency, mammalian genomes are also frequently healed by NHEJ in S/G2 [5]. 
The mechanism by which NHEJ rejoins a DSB is fairly understood. First, DSB are recognized 
by a heterodimer formed by Ku70 and Ku80 proteins [6]. Ku proteins display a ring-like 
structure and are able to bind and stabilize the ends of DSB, acting as sensors, and 
subsequently attracting the transducer kinase, DNA-PK (DNA dependent protein Kinase). 
DNA-PK is a large Ser/Thr kinase (about 470 Kda), which belongs to the PIKK family (PI3-
kinase like family of protein kinases). Other members of this family, ATM (ataxia 
talangectasia mutated) and ATR (ATM and RAD3-related), are key kinases in the DDR and 
will be explained in futher detail below. Once DNA-PK is located to the DSB it becomes 
activated and phosphorylates several substrates involved in the processing and ligation of 
DNA ends. Significantly, DNA-PK can also auto-phosphorylate in several residues, which 
seems to be essential for its repair capacity [7]. 
Finally, the main effectors of NHEJ form a multimeric complex (DNA Ligase IV-XRCC4-
XLF), which is recruited to DSB and activated by DNA-PK dependent phosphorylation. This 
complex is responsible for the actual rejoining of the ends [8]. Ligase IV provides the 
catalytic activity for the rejoining, while XRCC4 stabilizes and stimulates its activity [9]. 
Ku70 and Ku 80 (sensors), DNA-PK (transducer) and DNA ligase IV and XRCC4 (effectors) 
are the core component of NHEJ. But often other accessory components are required for the 
conversion of altered broken ends. For instance, DSB produced by IR usually requires an 
end-processing step prior to relegation, such as the one regulated by Artemis, a 5’- 3’ 
exonuclease, that acquires endonuclease activity when phosphorylated by DNA-PK [10]. 
This activity of Artemis is important to open closed hairpins in which the two strands of the 
DSB have linked together. Importantly, such hairpins are normally generated at the DSB 
generated by RAG nucleases during V(D)J recombination. Note that ATM can also induce 
the phosphorylation and activation of Artemis [11]. In fact, and in addition to be important 
for the repair of accidental DSB, NHEJ carries out several specialized functions in 
lymphocytes during V(D)J and CSR [12, 13]. Accordingly, patients with mutation in 
Artemis, ATM or DNA-PKcs, as well as in other NHEJ components, often suffer from 
immune deficiencies as well as from an increased predisposition to cancer [14].  
Another context in which difficult-to repair DSB are formed relates to chromatin 
accessibility. For instance, it is estimated that around 10% of radiation induced DSB are 
repaired with slow kinetics, this population being enriched adjacent to compacted 
chromatin (heterochromatin). In this case, ATM and not DNAPK will play an important role 
in the NHEJ-mediated repair of these difficult-to-repair breaks. In this context, ATM 
activation is necessary to phosphorylate some substrates like H2AX or KAP1, which would 
relax chromatin compaction allowing the access of repair proteins to DSB at 
heterochromatin [11, 15]. Nevertheless, it should be noted that the main cell-type that suffers 
from ATM deficiency is Purkinje cells which are almost devoid of heterochromatin, so that 
ATM must play additional roles in euchromatin [16].  
 
Protein Phosphorylation in Human Health 
 
236 
2.2. Homologous recombination 
The other mechanism that cells use for DSB repair, and the most important for replicating 
cells, is Homologous Recombination. In contrast to NHEJ, during HR DSB need to be first 
extensively processed to allow for the search of the homologous undamaged template. First, 
ends undergo 5’-3´ resection producing two single stranded DNA regions. Rad51-coated 
ssDNA stretches invade the sister chromatid DNA duplex forming inter-strand structures. 
How these heteroduplexes are finally resolved is still not fully characterized. 
Since HR repairs DSB using the sister chromatid as template, it is restricted to S and G2 
phases. Restricting HR in G1 is in fact critical, since if HR takes place in G1 it could lead to 
loss of heterozigosity (LOH) or chromosomal translocations [17]. To avoid this problem the 
activity of several HR components is regulated by several S-G2 specific CDKs (cyclin 
dependent kinases) [18].  
For teaching purposes, and trying to simplify the complex process that takes place during 
HR, we will artificially divide it in 4 independent stages. We acknowledge that many of the 
stepwise events described here are still to be fully validated, but just want to transmit a 
holistic view of how a DSB can be sensed, signaled and repaired by HR: 
a. Recruitment to the DSB: Foci forming factors 
The Mre11-Rad50-Nbs1 (MRN) complex is one of the first in being recruited to DSB [19]. 
Next, through a direct interaction, MRN recruits ATM which, among other things, 
phophorylates H2AX (a variant of the canonical histone H2A) at serine 139, forming γH2AX 
[20]. Direct phospho-binding to γH2AX recruits the adaptor protein MDC1 [21], which 
through interaction with ATM and Nbs1 forms a positive feedback loop that amplifies the 
γH2AX signal [22]. In addition, ATM-dependent phosphorylation of MDC1 is recognized by 
the E3 ubiquitin ligase RNF8, that ubiquitinates histones in the vicinity of the DSB [23, 24]. 
Another E3 ubiquitin ligase, RNF168 (mutated in the human RIDDLE immunodeficiency 
syndrome), is also recruited and amplifies the ubquitylation signal, in both cases mediated 
by UBC13 E2 ligase, eventually recruiting 53BP1 and BRCA1 to DSB-associated foci [25-27]. 
In the case of BRCA1, RAP80 binds to ubiquinylated substrates at DSB through its UIM 
(Ubiquitin Interaction Motif) [23]. RAP80 then interacts with Abraxas [28], the 
deubiquitylating (DUB) enzyme BRCC36 and BRCA1 (breast cancer 1, early onset). BRCA1 
is a well known human breast cancer susceptibility gene, responsible for the third part of 
familiar breast cancer [29]. BRCA1 is a large protein (over 200 kDa) that is constitutively 
bound to BARD1. Together, BRCA1/BARD1 present E3 ubiquitin ligase activity [30]. 
Although BRCA1 has been the subject of many studies and it is known to participate in HR, 
its exact role(s) and whether its ubiquitin ligase activity is critical for its activity is still not 
well understood. Whereas the road from DSB to BRCA1 is more understood, how 53BP1 is 
loaded to substrates modified by RNF8/RNF168 remains unknown. 
Importantly, it should be noted that all of these events have been inferred from the 
formation or absence of foci at DSB and, to date, it is not clear to what extent capacity to 
recruit to foci represents an accurate measurement of the function of the protein [31]. 
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b. Processing of the end: Resection 
As mentioned before, the resection of the two 5’ ends of the DSB is an essential step for HR. 
Three exonucleases (Mre11, Exo1 and CtIP) and one helicase (BLM) have been involved in 
resection [32-34]. Importantly, ATM dependent phosphorylation seems to stimulate CtIP-
mediated resection, linking DNA damage signaling with the processing of DNA ends [35]. In 
addition to ATM, ssDNA is quickly coated by RPA (replication protein A) and triggers a 
parallel pathway resulting in the activation of the kinase ATR [18, 36-38], that will be described 
below. It remains to be seen to what extent ATM, ATR, and perhaps DNA-PK collaborate in 
the processing of DSB for HR. One important recent development is the finding that, against 
all expectations, 53BP1 might limit resection [39]. This would explain how the absence of 
53BP1 rescues the cancer and ageing phenotypes of a BRCA1 mutant mouse model, which 
could be explained by an improved HR through enhanced resection [40].  
c. Sister chromatid invasion 
The initiation of recombination requires the loading of the recombinase Rad51, which 
replaces RPA coating on the ssDNA. Rad51, a protein with DNA-dependent ATPase 
activity, together with other associated proteins (DSS1, RAD52,RAD51B, RAD51C, RAD51D, 
XRCC2, XRCC3, RAD54, etc.) form a nucleoprotein filament that mediates strand invasion 
of the sister chromatid [41]. In mammals, Rad51 loading is mediated by BRAC2 [42]. Once 
again, BRCA2 is another important breast cancer susceptibility gene suggesting a critical 
role of HR in the prevention of breast cancer [43]. In contrast to BRCA1, BRCA2 recruitment 
to DSB is not fully understood, one possible scenario being that BRCA1 could mediate the 
recruitment of FancD2 and BRCA2 to DSB [44]. 
The nucleoprotein filament (ssDNA, RAD51 and other HR proteins) searches for an 
homologous region within the duplex DNA in the sister chromatid and displaces a DNA 
strand forming a D-loop structure and the 3’ end of the invading strand. This invading end 
then is extended by un unknown DNA polymerase (in vitro data indicates that DNA pol eta 
may be implicated [45]). The “X” shaped structure formed as a consequence of this invading 
process is called a Holliday Junction (HJ) [46]. When the other 3’ end of broken DNA enters 
the D-loop a double Holliday junction structure is formed. Noteworthy, whereas this model 
was proposed almost half a century ago, it was only recently that evidence for the double 
Holliday junction intermediates of repair was found [47] 
d. Resolution 
If HJ formation was remained elusive, the resolution of Holliday junctions is even a bigger 
mistery, many proteins having been proposed as candidates to be the HJ “resolvase”. Such a 
protein should have helicase and nuclease activities, like BLM (Bloom syndrome protein), 
MUS81-EME1 complex or GEN1 [48-51]. All of them have been proposed to be the missing HJ-
resolvase at some point. Moreover, recent evidence suggests that another enzyme, SLX4, could 
be such missing link [52, 53]. Whereas it seems clear that many proteins can deal with HJ-
resembling structures in vitro, only clean genetic data will finally resolve this “resolution” 
problem. We should mention that although the HR classical model consists in the formation of 
these two Holliday Junctions, there are other alternative models that explain the HR process. 
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In addition to its role at DSB, HR also has a key role in restarting stalled replication forks 
(RF). SSBs, interstrand crosslinks or other lesions in the DNA promote stalling of the RF 
which, if persistent, could lead to breakage that has to be resolved by HR [54]. ATR, another 
PIKK kinase that is essential for an appropriate progression of RF, may be regulating HR in 
this case. In fact, ATR and its target kinase Chk1 phosphorylate a number of HR-related 
proteins such as BRCA1, BLM and Rad51 [55-57].  
HR also participates in the maintenance of telomere length, by promoting inter-telomeric 
HR in the absence of telomerase. This pathway is known as alternative lengthening of 
telomeres (ALT) [58]. Finally, HR is the repair pathway of the recombination reaction that 
occurs between homologous chromosomes in meiosis, where DSB are intentionally 
generated in order to increase genetic variability. 
Whereas we here provided a simplified view of DSB repair, it should be noted that other 
still poorly understood pathways of repair such as micro-homology directed NHEJ, which 
joins partially resected DSB, are emerging as important genome caretakers. 
3. Signaling DSB 
We here present a general view of how cells signal DSB, with a particular emphasis on 
phosphorylation, which is the most known mechanism to date.  
3.1. Phosphorylation. The so-called DNA Damage Response (DDR) 
The so-called DDR stands for a coordinated signaling response which starts at the DSB and 
which promotes DNA Repair while it limits the expansion of the damaged cell by apoptotic 
or cytostatic mechanisms. The canonical DDR begins with the activation of two PIKK, ATM 
and ATR, upon detection of DSB. The role of DNA-PK, another member of the PIKK family, 
is mainly to stimulate repair activities locally at the break but without triggering a cellular 
response. Thus, ATM and ATR are considered the main upstream kinases in the signaling of 
DNA damage. Whereas they are activated by different types of damage and have some 
specific substrates and functions, their “response” is frequently interconnected. The 
activation of any of these kinases starts a phosphorylation cascade leading to cell cycle arrest 
(Checkpoints). Among others, the tumor suppressor p53 plays a central role in coordinating 
the apoptotic and checkpoints initiated by DNA damage.  
In the last decade the knowledge about the DDR has substantially increased, and besides the 
classical activation of the PIKK and phosphorylation cascades, other types of signaling such 
as ubiquitylation or sumoylation have burst [59]. A general overview of this complex 
pathway will be explained below. 
3.1.1. Central players of the DDR: PIKK kinases: ATM, ATR and DNA-PK 
The DDR has a well defined hierarchy. Their components have been classified into sensors, 
transducers, mediators and effectors. ATM and ATR kinases are considered the main DDR 
transducers. 
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As mentioned, ATM, ATR and DNA-PK belong to the PIKK (phosphatidylinositol-3-kinase 
related kinases) family [60]. They are large proteins (more than 300 kDa) with similar structure: 
a variable number of repeat domains in the N-terminus (HEAT domains), a FAT domain, a 
catalytic domain homologue to that in PI-3-Kinase (PI3K), a PIKK regulatory domain (PRD) and 
a FATC domain at the very C-terminus [61]. The PRD domain has been shown to mediate 
kinase activation, at least for ATR; and HEAT, FAT and FATC domains may be involved in the 
specific interactions of these proteins with their substrates and modulators [62]. 
ATM, ATR and DNA-PK specifically phosphorylate serine and threonine residues 
frequently followed by a glutamine. Upon activation, they are able to phosphorylate 
hundreds of common substrates regulating many cellular functions [63]. Noteworthy, some 
of them are preferred by one specific kinase, which is likely due to mediators. For instance, 
whereas all three can phosphorylate H2AX, Chk1 is only phosphorylated by ATR and this is 
explained by the need of Claspin in mediating the ATR/Chk1 interaction. 
Despite their similarities, these kinases play different roles in the DDR. In brief, DNA-PK is 
activated in response to DSB and promotes their repair by NHEJ. However, if DSB are 
located in heterochromatin or they are too numerous, ATM activates additional repair 
mechanism (e.g. HR) and starts checkpoints signaling. In addition, ATR is activated by 
ssDNA, generated when DSB persist and are ressected into ssDNA, or when a replication 
fork is collapsed, promoting a strong checkpoint signaling. Besides, whereas ATM and 
DNA-PK are active through all the cell cycle, ATR activity is confined only to S and G2 
phases [64]. One possible scenario is that the activity of the three kinases follows a stepwise 
activation if a DSB persist. This model is explained below. 
a. DNA-PK. Stimulation of DNA Repair 
The first step in this model will be the immediate activation of DNA-PK at a DSB. 
Previously in this chapter, we described how DNA-PK is activated and promotes NHEJ. In 
summary, the dimer Ku70/Ku80 binds and stabilizes the DSB ends, it recruits DNA-PK that 
activates the NHEJ effectors, LigaseIV-XRCC4-XLF. Thus, DNA-PK will provide a fast 
repair mechanism for easy-to-repair breaks, without the activation of checkpoint activities. It 
must be emphasized again, that DNA-PK has a very limited role in checkpoint signaling. 
However in the absence of ATM, DNA-PK may stay longer at the DSB and contribute to 
checkpoint functions [65]. 
b. ATM. DSB sensing and ATM Activation 
If the DSB persist, one plausible scenario is that ATM could phosphorylate and displace 
DNA-PK from the DSB, so that repair and checkpoint activities are implemented. ATM is 
the most studied and likely best known DDR kinase. One reason for this is that its absence is 
responsible for the human Ataxia-Telangiectasia (A-T) hereditary disorder [66]. A-T is a 
severe autosomal recessive disease characterized by early onset progressive cerebellar 
ataxia, oculocutaneous telangectasia, immunodeficiency and lymphoid tumours [67]. 
Immunodeficiency and predisposition to lymphoid tumours is explained by the role of ATM 
during T and B lymphocyte development, where DSB are generated as by-products of 
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immune rearrangements. Besides, cells of these patients present numerous breaks, what 
explains their increase predisposition also to other cancer types.  
Whereas it seems clear that the main role of ATM is related to the DDR [68], the two 
symptoms that named the disease, ataxia and telangiectasia, are still not explained by the 
role of ATM in relation to DNA damage, suggesting that ATM may have other functions not 
related to DSB-signaling. Moreover, even though we have significant understanding of the 
effects of ATM activation, how this is accomplished is still a matter of debate. 
As described above, ATM activation is triggered by the recruitment of the MRN complex 
(sensor) in response to DSB (Figure 2). MRN complex recruits ATM and collaborates for its 
activation [69]. However, the precise mechanism by which ATM becomes activated is still a 
matter of controversy [62]. Some authors claimed that, in basal conditions, ATM is an 
inactive homodimer which undergoes dissociation and activation in response to DSB, due to 
its autophosphorylation [70]. Importantly, it has later been shown that ATM 
autophosphorylation is not necessary for its activation in vivo [71, 72]. 
 
Figure 2. Mechanisms of ATM and ATR activation. A) ATM activation. DSBs (red asterisk) are sensed 
by the MRN (Mre11-Rad50-Nbs1) complex which attracts ATM and probably contributes to its 
activation. It is not well established how ATM is converted from its inactive to active status, one 
possibility being that it changes from an inactive dimer to an active monomeric form. B) ATR activation. 
The input for ATR activation is ssDNA, which can derive from resected DSB (left), or from stalled 
replication forks (right). RPA coated ssDNA loads the ATRIP-ATR complex and the 9-1-1 complex, 
which brings together ATR and its allosteric activator TopBP1.  
Nbs1, part of the MRN complex, could contribute to ATM phosphorylation and activation 
[73], and several other proteins, such as the histone acetyl transferase Tip60 [74], have been 
reported to be involved in ATM activation. In vitro, ATM can be activated in the absence of 
MRN members. However, the MRN complex amplifies ATM activity and collaborates for an 
optimal ATM accumulation surrounding the DSB [75]. Noteworthy, defects in two members 
of the MRN complex cause A-T related syndromes: Nijmegen breakage syndrome (NBS1 
mutants) and A-T-like disorder (MRE11 mutants) [76, 77]. 
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ATM has been claimed to be activated by other stimuli rather than DNA damage, like 
chloroquine or osmotic shock [70]. However, whether those stimuli do not generate damage, 
particularly during replication, remains to be seen. There are some evidences of a 
cytoplasmic fraction of ATM that might be helpful to explain part of the symptoms of A-T 
disease not related to the DDR like the early neurodegeneration. Of note, ATM in neuronal 
cells has been found predominantly cytosolic [78]. 
c. ATR. Activation by ssDNA 
The last (in fact, its activation occurs later than ATM) main PIKK kinase in the signaling of 
DSB is ATR. As noted before, despite their homology, ATR responds to different types of 
stresses than ATM does, and although these two kinases share several substrates, ATR 
regulates different processes. ATR has an essential role during replication, sensing 
alterations in fork progression and activating cellular checkpoints if necessary [79, 80]. 
In contrast to ATM, ATR is essential at the organism and the cellular level [81]. Consequently 
there is not any human disease lacking ATR. However, patients of a very rare ATR-related 
disease known as the Seckel syndrome are alive with very low amounts of ATR [82]. 
The input for ATR is not the DSB itself, but rather unusual large strands of ssDNA that can 
be generated in several circumstances [64]:  
- RS (replication stress) is a not well defined concept that refers to a variety of alterations in 
the normal progression of the replication fork, caused by lesions encountered in the 
DNA (SSBs, crosslinks, base adducts), dNTPs deficiency or other problems at the RF. 
When RS is prolonged or, in the absence of ATR, RF collapse and DSB are generated. 
Notice that there is no such a thing as RS-free replication, and thus ATR is essential to 
complete replication even in the absence of exogenous DNA damage. 
- End resection of DSB. Initially DSB lead to DNA-PK and ATM activation. However if 
DSB occurs in S or G2 phases and they persist enough, DSB are resected by ATM-
stimulated exonucleases generating strands of ssDNA which then activate ATR.  
- Telomeres. ssDNA can be also generated at uncapped telomeres that have lost its 
capping function, leading to ATR activation. 
- NER (nucleotide excision repair). The process of NER can generate patches of ssDNA as 
repair intermediates, which lead to the activation of ATR, perhaps even in G1 [83].  
In contrast to ATM, the molecular mechanism of ATR activation by ssDNA is well 
established (Figure 2). RPA-coated ssDNA [84] recruits the ATR-ATRIP (ATR interacting 
protein) complex [85]. At the same time, Rad17 and subsequently the 9-1-1 (Rad9-Rad1-
Hus1] complex are also brought to the damage sites by RPA [86]. The 9-1-1 complex, with a 
PCNA-like clamp conformation, then brings the allosteric activator TopBP1 (topoisomerase-
binding protein 1] into close proximity of ATR [87]. The interaction of ATR with TopBP1 is 
then sufficient to unleash ATR activity [88]. Of note, activation of ATR by TopBP1 even in 
the absence of DNA breaks is sufficient to promote a robust cellular response including 
senescence, demonstrating the key role of the DDR in responding to DNA damage [89].  
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3.1.2. Mediators and DDR amplification. Foci forming factors 
Downstream of the PIKK, DDR signaling is amplified by several mechanisms, allowing the 
response to achieve its final cellular outcomes. On one hand, the DDR, like any other 
phosphorylation cascade, amplifies its signal in subsequent (enzymatic) step. This involves 
the participation of mediators, which are proteins acting downstream of the transducer 
kinases ATM and ATR. Several substrates, regulators, recruiters and others proteins acting 
as scaffold are considered mediators (e.g. Mdc1, 53BP1, MRN complex, Claspin, BRCA1), 
and, they modulate the activation of the effectors. Another mean of amplifying the signal, is 
an intense accumulation of many of their components surrounding the DNA lesions in spots 
so-called IRIF (Ionizing Radiation Induced Foci). 
Once ATM or DNA-PK are activated, the rapid phosphorylation of the histone H2AX 
(H2AX) is key for subsequent events. The H2AX mark is accumulated in such a large 
amount in the proximity of DSB that can be visualized in spots (IRIF) by standard 
immunofluorescence techniques. Many DDR proteins (MRN complex, ATM, 53BP1, BRCA1 
and others) form IRIF that co-localize with H2AX foci. Actually, H2AX modulates the 
accumulation of repair and signaling proteins in chromatin regions distal to the DSB. 
However, this has nothing to do with the recruitment of the proteins to the DSB, and rather 
by altering chromatin conformation in the vicinity of the break [90]. But what are foci good 
for? One likely possibility is that the accumulation of DDR proteins surrounding DNA 
lesions is necessary to build a signaling threshold in conditions of limited damage [91]. 
Among the different factors, 53BP1 is probably one of the most studied examples of an IRIF 
forming protein. 53BP1 has a pan-nuclear location which, after exposure to genotoxic agents, 
is quickly repositioned to IRIF. 53BP1 localization into foci is dependent on several 
upstream events including H2AX phosphorylation [90], recruitment of MDC1, 
ubiquitinating activity of RNF8 and RNF168 [23, 25, 92, 93], and methylation of histones H3 
and H4 [94, 95]. Regardless of their importance for our understanding of the DDR, the 
absence of foci does not seem to be essential for a proficient DDR. Thus, mouse models 
lacking H2AX or MDC1, that abolishes IRIF formation, as well as 53BP1 null mice, are 
viable, but they exhibit phenotypes related to DDR deficiency like genome instability, cancer 
predisposition or immunodeficiency [22, 96, 97]. In summary, while not essential, IRIF seem 
to modulate the amplitude of the signaling of DSB which might be important in conditions 
of low numbers of DSB. 
In contrast to ATM, ATR does not undergo any post-translational modifications which 
would modify its activity, such as autophosphorylation. Nevertheless, a number of 
mediators of ATR signaling are indeed regulated through phosphorylation. For instance, the 
ATR activator TopBP1 is phosphorylated by ATM at resected DSB [98]; and probably also 
by ATR in response to RS. In addition, Claspin phosphorylation is also required for ATR-
dependent phosphorylation of Chk1 in response to DSB [99]. 
In summary, ATM and ATR signaling are amplified and driven by these and many other 
mediators. The endpoint of the signaling cascade arrives with the activation of the effectors, 
which would finally be responsible for the cellular responses.  
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3.1.3. Effectors and cellular outcomes of the DDR 
In addition to promote the repair of DNA lesions, the DDR can orchestrate multiple cellular 
responses orientated to safeguard genome integrity or, in some cases, to avoid transmission 
of harmful alterations by activating apoptosis or senescence. In this context, one of the main 
effectors of the DDR is the transcription factor p53 which provides a late sustained response 
to DNA damage. p53 up-regulation contributes to the activation of checkpoints, and, if the 
damage persists, may activate senescence, apoptosis or cell differentiation programmes. 
Regardless of this p53-centric view, it is clear that many p53-independent pathways are also 
stimulated by the DDR. For instance, a single proteomic study identified more than 700 
ATM/ATR phosphorylation substrates, pointing out the wide variety of effectors and 
pathways that are regulated by the DDR [63]. 
Given that there are multiple reviews elsewhere that focus on these cellular responses, we 
here only briefly describe the main cellular responses promoted by the DDR: cell cycle 
checkpoints, senescence, apoptosis and differentiation. 
3.1.3.1. Transient cell cycle delay: Checkpoints 
The transitions through the different stages of the cell cycle are tightly regulated by the 
activity of cyclin-dependent kinases (CDKs). CDKs are activated by cyclins and inhibited by 
CDK inhibitors (CKIs) or inhibitory tyrosine phosphorylations [100]. In brief, a simplified 
scheme depicts that four CDKs are involved in the regulation of cell cycle; CDK2, CDK4 and 
CDK6 during interphase, and CDK1 being considered the mitotic CDK. An activated DDR 
can limit the activity of CDKs and thus prevent cell cycle progression into the next stage 
(G1/S and the G2/M). In addition, the DDR can also slow down replication (intra-S 
checkpoint), but this is not a full stop and cells with damage in S-phase progress into G2 
stop at the G2/M checkpoint [101]. The way that the DDR gets to the CDKs is through 
effectors that limit CDK activity which we now briefly summarize. 
First, the main PIKK targets that regulate checkpoints are the so-called checkpoint kinases 
Chk1 and Chk2, direct substrates of ATR and ATM respectively [102, 103]. Checkpoint 
kinases act by regulating CDK inhibitory effectors such as Cdc25a, Wee1 or p53. Cdc25a is a 
phosphatase that controls CDK1 and CDK2 activities. In response to DNA damage, ATR-
activated Chk1 phosphorylates Cdc25a inducing its degradation [104, 105], and thereby, 
inhibition of CDK activity [106]. An opposing force for Cdc25a is Wee1, the kinase that 
counteracts Cdc25a activity. Finally, a major mediator of cellular responses to DNA damage 
is p53. p53 is rapidly stabilized upon DNA damage by a number of inter-dependent PTMs. 
ATM, ATR, Chk1 and Chk2 are all able to phosphorylate p53 contributing to its stabilization 
[107, 108]. Besides its apoptotic targets, p53 has a number of transcriptional targets that 
contribute to checkpoint function, perhaps the most notorious being the CKI p21cip1 which is 
an important regulator of the G1/S checkpoint.  
Specifically, the G1/S checkpoint avoids the replication of damaged DNA (see Figure 3 for a 
scheme of checkpoint responses). The transition from G1 to S is directed by an increase in 
CDK2 activity induced by cyclin E [109]. As such, the G1/S checkpoint is directed to limit 
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this burst in CDK activity. An early and late component checkpoint can be separated. First, 
the G1/S checkpoint is initiated by degradation of Cdc25a, leading to the accumulation of 
inhibitory phosphorylations on CDK2 [110, 111]. This is an early response that does not 
require the synthesis of new proteins. If the damage persists, p53-dependent transcriptional 
upregulation of p21cip1 would implement a stronger G1/S arrest [112].ATM and Chk2, but 
not ATR/Chk1 are the main DDR mediators of the G1/S transition. 
 
Figure 3. Chekpoint regulation by the DDR. ATM and ATR orchestrate a transitory delay of the cell 
cycle in response to DSBs and ssDNA, respectively. Wherease direct phosphorylation of of cdc25a and 
wee1 allow a rapid establishment of the G1/S and G2/M checkpoints, p53-dependent regulation 
contributes to checkpoint maintenance at later timepoints. During S and G2 phases DSBs can be 
resected leading to the generation of ssDNA, which also activates ATR-signaling. 
If damage arises in S phase, the intra-S checkpoint is also mainly regulated by the 
phosphatase Cdc25a, but now under de control of ATR and Chk1 [102]. In addition, DDR-
promoted replication inhibition is in part mediated by Cdt1, which participates in the 
loading of MCM helicases that facilitate DNA unwinding ahead of the RF [113]. How the 
DDR promotes Cdt1 degradation and thus replication control is yet uncharacterized. 
The last key control point is the G2/M checkpoint, that “checks” genome integrity before 
proceeding into chromosome segregation. Here, the transition from G2 into M is governed 
by an increase cyclinB-CDK1 activity. Once again, this checkpoint is also established by 
Cdc25a phosphorylation, in this case mediated by the ATR-dependent Chk1 kinase. In 
addition, the kinase Wee1 also contributes to the G2/M checkpoint. In a normal G2/M 
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transition Plk1 (Polo kinase 1) phosphorylates Wee1 inducing its degradation and entry into 
mitosis. Upon damage ATM and ATR are able to phosphorylate and inhibit Plk1, 
contributing to an increase of Wee1 and therefore reduced CDK1 activity [100]. In addition 
to this early checkpoint, p53 also regulates the maintenance or sustained G2/M arrest. In this 
case, rather than mediated by p21, which has little CDK1 inhibitory capacity, other p53 
targets such as GADD45 and 14-3-3 act as effectors [114]. 
3.1.3.2. Permanent cell cycle arrest: Senescence 
By definition, checkpoints are a transitory state from which cells can escape if repair is 
accomplished and the signal is turned off. In contrast, cellular senescence is a persistent and 
irreversible cell cycle arrest. It was firstly observed in cell culture in 1965 [115]. Depending 
on the load of DNA damage or the cell type, a persistent activation of the DDR might direct 
cells into senescence [89].  
Besides the presence of DSB, other cellular stresses can also promote senescence. These 
include telomere shortening [116], oxidative stress [117] and oncogenes [118-121]. 
Nevertheless, all of these stimuli can activate the DDR, so that DNA damage might be the 
ultimate cause of the senescent response. First, short or unprotected telomeres resemble and 
are actually sensed by cell as DSB [122, 123]. Second, reactive oxygen species generated by 
oxidative stress are an obvious source of DNA damage. Finally, several oncogenes have 
been shown to induce RS so that oncogene-induced senescence (OIS) would be linked to the 
DDR [124-126]. Importantly, and as it will be discussed below, OIS has been suggested as an 
early anti-cancer barrier in vivo, providing a link between the DDR and cancer development 
[127]. However, it must be pointed out that alternative, DDR-independent pathways of 
promoting OIS and which operate through the Ink4a/ARF locus have been described [128]. 
3.1.3.3. Apoptosis 
Apoptosis, or programmed cell death, is other phenomenon activated by the DDR in order to 
eliminate cells with intolerable amounts of DNA damage. As such, apoptosis has an important 
role in eliminating damaged cells during aging [129] or in the acute responses genotoxic cancer 
therapies. In addition, apoptosis is a physiological process essential for normal development.  
As in the case of senescence, apoptosis is also chiefly governed by p53. DDR-induced p53 
promotes the expression of several pro-apoptotic factors, such as Puma, Noxa and Bax [130-
132]. This pro-apoptotic p53 program leads to mitochondrial membrane permeabilzation 
[133], allowing the exit of cytochrome c to the cytosol, forming the apoptosome, which 
finally activates effector caspases [134]. 
Why some cells undergo apoptosis and other senescence in response to DNA damage is still 
a matter of study [135]. Although most cells are capable of both phenomenons, cell type is 
indeed determinant to undergo one or another. For instance, whereas DNA damage in 
fibroblasts and epithelial cells specially promotes senescence, low amounts of DNA breaks 
in lymphocytes are sufficient to trigger apoptosis. Of note, post-mitotic cells like neurons, 
have a limited capacity to become senescent or undergo apoptosis which might be due to 
their particular cell cycle status. 
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3.1.3.4. Other cellular pathways stimulated by the DDR 
Given the large amount of PIKK phospho-targets and p53 transcriptional targets it is not 
surprising that the DDR exerts its function in many cellular processes by means that remain 
poorly understood. For instance, high doses of DNA damage can induce the differentiation of 
melanocyte stem cells (SC), resulting in their depletion and thereby promoting aging 
phenotypes on the skin [136]. Similar results linking the DDR and differentiation have been 
found in neurons [137]. Related to this, p53 has been shown to regulate the polarity of 
mammary cancer stem cell divisions [138]. p53 loss promotes symmetric and promiscuous 
cancer stem cell divisions, which contribute to the expansion of premalignant pools. It is 
therefore tempting to speculate that one of the means by which DNA damage leads to stem 
cell exhaustion is by promoting p53-dependent asymmetric cell divisions in SC. 
Finally, another process that might be modulated by DNA damage is autophagy, which functions 
to promote cell survival through the degradation of damaged organelles and molecules. 
Interestingly, one of the key regulators of autophagy is mTOR (mammalian target of 
Rapamycin), another member of the PIKK family. Whereas the mechanism remains to be solved, 
recent studies suggest a connection between the DDR and mTOR that could be the responsible 
for DNA damage induced autophagy [139, 140]. To what extent these additional effects of the 
DDR impact on the physiological consequences of a deficient DDR, remains to be seen. 
3.1.4. Physiological consequences of the DDR 
DDR deficiencies cause important physiological consequences. As commented on this 
chapter, DSB are physiologically generated during B and T lymphocyte maturation and 
during meiotic recombination, and many DDR-related proteins are required for normal 
functioning of these processes. In addition, the DDR has an essential role in facing the 
stochastic DNA damage that our cells acquire through our lifetimes. In this context, it is not 
surprising that deficiencies in DDR components cause human diseases associated to 
immune deficiencies, sterility, premature aging and cancer predisposition. Alterations 
during embryonic development are also frequent, suggesting that the high division rates 
occurring at this stage might be prone to accumulate DNA damage, particularly RS.  
DDR-mutant mouse models recapitulate many of the phenotypes found in DDR-associated 
human syndromes. Some of the most relevant DDR-related diseases are shown in table 1. 
Most of them are of recessive nature, with some exceptions such as variants of Li-Fraumeni, 
which can be caused by dominant mutations in just one allele of p53. 
3.1.4.1. The DDR and cancer: Protector and target 
The relationship between the DDR and cancer is of particular interest from multiple points of 
view. First, the DDR is critical to prevent the accumulation of spontaneous pro-cancerous 
mutations and overall genomic instability. This is why most DDR-related human diseases are 
prone to cancer development. In addition, the DDR is particularly relevant in preventing 
chromosome rearrangements during lymphoid maturation which makes lymphomas one of 
the most frequent cancer in Genomic Instability Syndromes. Note that in some cases mutations  
 




Disease Mutated gen Clinical feature




Nbs1 Growth retardation, microcephaly, immunodeficiency, 
lymphoid tumours. 
A-T like disorder Mre11 Cerebellar ataxia, mild predisposition to tumours. 
Seckel Syndrome ATR Progeria, microcephaly and other developmental defects. 
Li-Fraumeni p53 Early development of cancer (breast cancer, sarcomas, brain 
tumours, leukemias, etc.) 
Riddle syndrome RNF168 Inmunodeficiency, dysmorphic features, mental retardation. 
Werner syndrome RECQL2 (WRN) Progeria and age-associated disorders 
Fanconi Anemia 13 different FA 
genes 
Bone marrow failure, predisposition to leukemias and solid 
tumours. 
Table 1. Several human genetic syndromes related to DDR components. 
in only one allele convey a dramatic increase in cancer predisposition. This is the case for 
BRCA1 and BRCA2 mutations carriers, whose life-time breast cancer risk raise up to 80%. 
Second, the DDR is activated by oncogenes in early stages of tumorigenesis [124, 141]. 
These studies proposed a model where the activation of certain oncogenes could generate 
RS which, by activating the DDR, would limit cancer development by promoting cell 
senescence [142, 143]. In fact, convincing evidence exists to show that certain oncogenes 
indeed are able to generate DNA damage trough promoting abnormal replication [124, 125]. 
Note that this type of damage, known as RS, is sensed and signaled mainly by ATR rather 
than ATM [83], raising the relevance of ATR-signaling in the oncogene-activated DDR 
model of cancer progression. 
Finally, many of the current anti-cancer therapies (including radiotherapy) operate by 
generating high loads of DNA damage that activate the DDR towards apoptosis. In this 
regard, there is increasing interest in the development of new anti-cancer strategies that take 
advantage of our knowledge of the DDR to specifically target tumor cells. The idea behind 
these new strategies is to exploit synthetic lethal interactions that will only occur in cancer 
cells. For instance, one of the most promising approaches in this regard is the use of PARP 
inhibitors for the treatment of BRCA1/2 deficient breast cancers. These inhibitors block a 
ssDNA repair pathway which is mostly dispensable for normal cells, but essential for cells 
deficient in HR, such as BRCA1/2 mutant cells [144]. Other examples of synthetic lethality 
could be the use of Chk1 inhibitors and ATR inhibitors, to treat p53 deficient tumors [145-148]. 
3.1.4.2. The role of the DDR in ageing 
Ageing is intuitively associated with the natural degeneration of our tissues, which would 
derive from the accumulation of some “toxic” factor. Studies mostly performed in the last 
decade have identified DNA damage as this deleterious factor that is associated to the onset 
of ageing [149, 150]. For instance, aged tissues or stem cells show evidences of an activated 
DDR [151, 152]. Moreover, most DDR-related genetic diseases suffer from premature ageing, 
which is likely due to a faster accumulation of intolerable amounts of DNA damage. 
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The most accepted theory is that DNA damage, when accumulated in SC, activates a DDR 
that limits their regenerative capacity and thus promotes ageing [151, 153]. To what extent 
DNA damage is the natural cause of actual ageing in humans, and which types of DNA 
damage (RS, eroded telomeres, ROS…) are most important in this process, remains to be 
understood. In what regards to RS, the faster nature of embryonic cell divisions might make 
this stage particularly susceptible to this type of damage. In fact, recent studies in ATR 
hypomorphic mice revealed that an intra-uterine exposure to RS can accelerate the later 
onset ageing [146, 154]. Whereas the exact mechanism of this intrauterine programming of 
ageing is not fully understood, it raises the question about to what extent our adult well-
being can be already conditioned by the stresses to which we were exposed in utero. 
3.2. Other posttranslational modifications in the DDR 
There is little doubt that PIKK-mediated phosphorylation is a major controller of the DDR. 
Nevertheless, to end this chapter we would want to describe the role that non-
phosphorylation based signaling of DNA damage might play in genome protection. In the 
light of recent discoveries, DNA damage signaling through other PTMs such as acetylation, 
methylation, ubiquitination and, sumoylation might also play crucial roles for appropriate 
DNA damage signaling. 
3.2.1. Ubiquitination 
Ubiquitination is a highly regulated process that promotes covalent modification of specific 
proteins substrates with the 76-amino acid protein ubiquitin, catalyzed in three sequential 
steps by E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme) and E3 (ubiquitin 
ligase) enzymatic activities [155]. Classically, ubiquitination (UQ) was described as a 
mechanism to target proteins for proteasome mediated degradation. However, at present, 
other functions of UQ such as during protein localization or in mediating protein-protein 
interactions are known. In fact, phosphorylation signaling (not only by the DDR) is often 
coupled to substrate ubiquitination, which increases the potential network of protein-
protein interaction [156, 157]. 
UQ presents seven lysines in its surface: K6, K11, K27, K29, K33, K48 and K63. Whereas 
poly-ubiquitination linked to K48 residues is usually related to proteasomal degradation 
[158], K63-linked polyubiquitin chains are more related to other regulatory functions [159]. 
In addition to the conjugating lysine, ubiquitin chains display an ample structural diversity, 
that has its counterpart in many different ubiquitin interactif motifs (UIM) in other proteins 
[160]. The role of UQ is counteracted by deubiquitianting enzymes (DUB), which are 
responsible for the elimination of UQ conjugates. 
Several ubiquitination events have been assoctaied to DSB signaling. As previously discussed, 
PIKK activation is followed by ubiquitination of various substrates. Again, ATM-dependent 
phosphorylation of H2AX and MDC1 are sufficient to recruit the E3 ubiquitin ligase RNF8. 
Together with another E3 ligase known as RNF168, and with Ubc13 as the E2 ligase, RNF8 
promotes the accumulation of ubiquitinylated substrates in the vicinity of the DSB. Of note, 
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RNF168 loading to foci occurs trough direct recognition of RNF8-deposited UQ chains through 
its UIM domains [25, 26]. These poly-ubiquitinations are mainly K63-linked and contribute to 
attract specific UIM-containing proteins and/or to modulate chromatin architecture via histone 
ubiquitinylation [159]. Recent works have shown that HERC2 (Hect Domain and RLD2) is an 
important regulator of RNF8 and RNF168-dependent ubiquitinitalion which mediates through 
promoting the binding to the E2 ligase Ubc13 [161]. 
This coordinated cascade of UQ modifications generated at DSB is necessary for the formation 
of BRCA1 and 53BP1 foci. However, once again, the absence of RNF8 does not lead to major 
BRCA1 phenotypes, which challenges the relevance of IRIF as predictors of functionality. It 
should be noted also that there is no evidence of direct binding of 53BP1 to ubiquitin chains, 
and how UQ mediates 53BP1 foci remains a mistery. In addition, 53BP1 can bind methylated 
histones which may provide an independent way of loading to DSB [94, 95, 162]. 
In contrast to 53BP1, the relationship of BRCA1 foci with UQ is well characterized. RAP80, a 
protein containing several UIMs in tandem, binds to ubiquitinated substrates (perhaps 
histones) [23], and brings Abraxas [28] and BRCA1. Interestingly, RAP80 also interacts with 
BRCC36, a DUB, which activity is also required for proper DSB repair and signaling [163, 
164]. Thus, ordered ubiquitinylation and deubuquitinylation may be needed during the 
signaling of DNA damage. 
The UQ pathway does not end with 53BP1 or BRCA1. BRCA1 itself is an E3 ubiquitin ligase 
activity resident in the N-terminal RING domain of this large protein. In fact, this is the only 
enzymatic activity found in BRCA1. While BRCA1 has E3 activity by itself, this activity 
increases in several orders of magnitude when bound to its constitutive partner BARD1 [30]. 
To date, the only well characterized BRCA1 substrates are BRCA1 itself and CtIP. CtIP 
ubiquitination by BRCA1 [165] has been proposed to promote the resection of DSB, leading 
to HR and a regulation of the G2/M checkpoint through ATR-activity. Hence, in this system 
UQ would be upstream of the phosphorylation DDR.  
To complicate things further, BRCA1 auto-ubiquitination is linked to K6, which is mediated by 
the E2 enzyme Ubch5c [166]. Ubiquitinated BRCA1 is found at DSB and also in several 
endogenous spots during S phase. Interestingly, even though 20% of human BRCA1 mutations 
predisposing to breast and ovarian cancer are found in the RING domain [30], recent data 
emerging from mouse models suggest that the E3 ligase activity of BRCA1 might be unrelated 
to genome maintenance and its tumor suppression role [167, 168]. However, other studies [169, 
170] indicate the importance of the RING domain in BRCA1 tumor suppressor function. 
Certainly, further work needs to be done to solve these divergent observations. 
Finally, regardless of DSB there is solid evidence that UQ-mediated signaling pathways also 
contribute to other genome protective pathways. For instance, UQ plays a key role in the 
Fanconi Anemia pathway. Fanconi Anemia (FA) is a recessive disease characterized by 
developmental abnormalities, bone marrow failure and cancer predisposition [171]. The 
disease is caused by mutations in at least 13 genes which mutations compromise the repair of 
interstrand DNA cross-links. A key event on the activation of the FA pathway is the 
monoubiquitination of FancD2 and FancI proteins, with is thought to be essential for its 
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localization at chromatin [44, 172, 173]. Again, there is evidence to suggest that FANCD2 
ubiquitinylation is downstream of ATR signaling, providing a further example of the constant 
interaction between the different signaling pathways that are activated by DNA damage [55]. 
3.2.2. SUMOylation  
SUMO stands for Small Ubiquitin-like modifier due to its similarities with UQ. In fact, 
SUMOylation is a similar process to ubiquitinylation involving E1, E2 and E3 enzymes. 
Importantly, very few SUMO E3 ligases exist in the mammalian proteome, which limits the 
search for potential ligases. In addition, SUMO E3 ligases are mostly dispensable and E2 
ligases can complete the SUMOylation reaction largely by themselves. In contrast to UQ, 
three SUMO variants (SUMO1, SUMO2 and SUMO3 exist [174].  
A number of SUMO roles with genome maintenance pathways have been discovered. In 
what regards to the DDR, two recent studies identified a SUMO-related signaling cascade 
that also coordinates the foci formation of BRCA1 and 53BP1 in response to DSB [175, 176]. 
At present, PIAS1 (Protein Inhibitor of Activated STAT-1) and PIAS4, are the E3 SUMO ligase 
enzymes found to participate in the DDR, using SAE1 (SUMO activating enzyme subunit 1) as 
E1 and UBC9 (Ubiquitin Conjugating Enzyme 9) as E2 enzymes. All these proteins, as well 
as SUMO1 and SUMO2/3 conjugates are rapidly recruited to DSB, forming IRIF. Whereas 
the mechanism is still not totally clear, it seems that PIAS1 promotes SUMO2/3 modification 
of BRCA1, and PIAS4 is mainly involved in SUMO1 modifications of both 53BP1 and 
BRCA1. Together, these SUMOylations seem to be necessary for RNF8 and RNF168 
function, providing another instance of inter-PTM signaling at DSB [175, 176]. A summary 
of key SUMO and UQ modifications in the DSB response is illustrated in table 2. 
 
E3 Ligase E2 Ligase Main substrates Function
Ubiquitinations
FancL Unknown FancD2 DNA Cross-link repair 




RNF8  Ubc13 H2A, H2AX DSB signaling 
RNF168 Ubc13 H2A, H2AX DSB signaling 
SUMOylations
PIAS1 Ubc9 BRCA1 DSB signaling 
PIAS4 Ubc9 BRCA1, 53BP1 DSB signaling 
Table 2. Relevant ubiquitinations and SUMOylations in genome maintenance. 
Regardless of the DDR, other genome maintenance pathways are also controlled by SUMO. 
One example is the role of a SUMO ligase called Mms21, which is an essential component of 
a cohesin and condensin related complex formed by Smc5 and Smc6 [177]. Whereas the role 
of this complex is far from being understood, it seems it might be important to prevent the 
accumulation of hemicatenates at stalled replication forks [178].  
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3.2.3. Interplay of PTMs in the DDR 
Other post-translational modifications, such as methylation and acetylation, are also 
involved in the regulatory network of the DDR. A paradigm of multiple and interconnected 
PTM is found in the regulation of p53 levels, that involves a coordinated network of 
phosphorylation, acetylation, methylation and ubiquitination [179].  
In the absence of DNA damage, p53 levels are kept low due to its ubiquitination by the E3 UQ 
ligase MDM2 and rapid degradation by the proteasome [180]. In fact, one of the ways by 
which DNA damage and other stress signals promote p53 stabilization is by PTMs which 
alters the MDM2/p53 interaction. p53 also suffers DDR-dependent phosphorylations [107] are 
thought to stabilize the protein and allow its association with the CBP/p300 acetyltransferase 
complex, promoting p53 acetylation and further stabilization [181]. Besides, p53 activity is 
limited by Set8/Pr-Set7 mediated methylations [182], which are also upon DNA damage [183].  
Another relevant example of the interplay between different PTMs in the DDR is found in 
histones. Indeed, post-translational modifications of histones regulate many other processes 
related to chromatin compaction and structure, such as replication and transcription. The 
best known histone modification upon DNA damage is the already described 
phosphorylation of H2AX, that it is mediated by ATM, ATR or DNA-PK [20]. We also 
discussed how RNF8 and RNF168 can ubiquitinate histones in the proximity of DSB [26, 92]. 
Finally, methylations of histones H3 and H4 could modulates the recruitment of 53BP1 [94, 
95, 162]; and several acetylations of histones have been described to play roles in genome 
maintenance which are still not completely understood [184-186]. How histone 
modifications enhance DSB repair is a very active area of research and discussion. One 
possibility is that histone modifications could increase chromatin accessibility, which would 
therefore facilitate the repair and signaling of the breaks [187]. 
4. Future perspectives 
We have here provided a general overview of how cells signal the presence of DNA 
damage, and how a proper signaling is necessary to maintain a healthy genome. Still, 
whereas the amount of PTMs that coordinate the cellular response to DNA damage is 
already intimidating, it is likely that we are only seeing the tip of the iceberg. Many other 
targets and even PTM (ADP-rybosylation, Neddylation, N-terminal glycosylation, etc…) 
will probably be involved in mounting a proper DDR. Without a doubt, the fast 
development of massive proteomic technologies will soon provide a breathtaking picture of 
how cells detect, signal and repair DNA breaks; by promoting a myriad of PTMs in almost 
every molecule involved in the DDR.  
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